Genus plc (LON:GNS), a leading global animal genetics company, has announced the appointment of Dr Ralph Heuser to the Board as a Non-Executive Director, with effect from 1 January 2024.
Dr Heuser has had extensive experience in animal healthcare businesses globally, having worked at Pfizer, Boehringer Ingelheim, where he launched a PRRS vaccine in Germany, Novartis’s Consumer and Animal Health divisions and more recently in global leadership roles at Elanco Animal Health, including as Vice President for Asia Pacific, Europe and International Commercial Operations. Dr Heuser has a PhD in Agricultural Economics from the University of Bonn, Germany and is currently a Senior Advisor with Stonehaven Consulting (SC Group) AG.
Dr Heuser brings widespread global experience in operations, commercial excellence, integration and the animal health industry generally, and his appointment follows an extensive search process using an external search agency.
Commenting on the appointment, Iain Ferguson, Chair of Genus, said:
“We are delighted to welcome Ralph to the Board. Ralph brings invaluable experience and knowledge of commercial strategy and operations in agricultural and animal health businesses across many global markets, which will allow the Board to maintain this area of expertise following the recent retirement of Lykele Van Der Broek from our Board. I would like to thank Lykele for his significant contributions to Genus over the last nine years and wish him every success for the future.”
